Product image of Linagliptin-Metformin Stada (Metformin Hydrochloride, Linagliptin) supplied by GNH India

Linagliptin-Metformin Stada

Active Ingredient:
Metformin Hydrochloride, Linagliptin
Origin:
EU

Linagliptin-Metformin Stada (Metformin Hydrochloride, Linagliptin)

Linagliptin and Metformin Hydrochloride, the active ingredient in Linagliptin-Metformin Stada, is a DPP‑4 inhibitor and biguanide presented as a tablet for oral use. It treats type 2 diabetes mellitus in adult patients by improving blood glucose control.

GNH India supplies Linagliptin-Metformin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Stada Arzneimittel Ag

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Linagliptin-Metformin Stada is used in the management of type 2 diabetes, targeting hyperglycaemia through combined mechanisms.
  • Type 2 diabetes mellitus: improves glycaemic control when added to diet and exercise.
  • Adjunct to metformin therapy: provides additional DPP‑4 inhibition for patients inadequately controlled on metformin alone.
  • Combination with other oral antidiabetics: used alongside sulfonylureas or SGLT2 inhibitors to achieve target HbA1c levels.

How It Works

  • Linagliptin selectively inhibits dipeptidyl peptidase‑4, prolonging incretin activity and enhancing glucose‑dependent insulin secretion. Metformin suppresses hepatic gluconeogenesis and increases peripheral insulin sensitivity, together lowering fasting and post‑prandial blood glucose levels.

Side Effects

The combination may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea.
  • Headache: mild to moderate intensity.
  • Upper respiratory symptoms: nasopharyngitis or sinus congestion.

Serious or Rare Side Effects

  • Lactic acidosis: rare but potentially fatal metabolic disturbance.
  • Severe hypersensitivity: skin rash, angioedema, or anaphylactic reactions.
  • Pancreatitis: acute inflammation of the pancreas presenting with abdominal pain.

Precautions & Warnings

  • Before prescribing Linagliptin-Metformin Stada, clinicians should consider several safety aspects.
  • Renal function assessment: evaluate creatinine clearance before initiation and periodically thereafter.
  • Hepatic function monitoring: avoid use in patients with severe liver disease.
  • Lactic acidosis risk: contraindicated in patients with conditions predisposing to hypoxia or severe infection.
  • Heart failure status: use with caution in patients with NYHA class III/IV heart failure.
  • Concomitant medication review: assess for drugs that may affect renal clearance or increase hypoglycaemia risk.
  • Store at room temperature: keep in the original container, protect from moisture and heat.

Avoid Interactions

Linagliptin-Metformin Stada can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

  • Iodinated contrast agents: may precipitate acute renal failure, increasing metformin accumulation risk.
  • Cimetidine: can raise linagliptin plasma concentrations, enhancing potential side effects.
  • Strong CYP3A4 inhibitors: may increase linagliptin exposure.

Moderate Interactions (Monitor Closely)

  • Diuretics and ACE inhibitors: may affect renal function, requiring dose adjustment of metformin.
  • Other antidiabetic agents: combined use can increase risk of hypoglycaemia.
  • Alcohol: can potentiate metformin‑related lactic acidosis.

Frequently Asked Questions

Linagliptin-Metformin Stada is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus, typically when diet, exercise, and monotherapy with metformin are insufficient.

Linagliptin blocks the enzyme dipeptidyl peptidase‑4 (DPP‑4), which results in higher levels of endogenous incretin hormones. These hormones increase insulin secretion and reduce glucagon release in a glucose‑dependent manner, helping lower blood sugar.

The prescribed dose is individualized by the treating clinician based on factors such as the patient’s renal function, current glycaemic control, concomitant medications, and overall treatment goals.

Safety data are limited; the product should only be used during pregnancy or lactation if the potential benefit justifies the possible risk, and this decision must be made by a qualified healthcare professional.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The fixed‑dose combination offers the complementary actions of a DPP‑4 inhibitor and a biguanide, providing effective glucose lowering with a single tablet. Compared with separate agents, it may improve adherence, but the safety profile remains consistent with the individual components.

Store the tablets at room temperature, below 25 °C, in the original packaging. Keep them away from moisture, direct sunlight and heat to maintain product stability.

The medication is taken orally, usually once daily with or without food, as directed by the prescribing physician. Swallow the tablet whole; do not crush or split unless specifically advised.

Serious adverse events include lactic acidosis (primarily linked to metformin), severe hypersensitivity reactions, and acute pancreatitis. Prompt medical attention is required if symptoms such as rapid breathing, abdominal pain, or skin swelling develop.

Patients with severe renal impairment, significant hepatic disease, a history of lactic acidosis, or known hypersensitivity to either component should avoid this medication. It is also contraindicated in individuals with type 1 diabetes or diabetic ketoacidosis.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT